Katie Doores

Source: Wikipedia, the free encyclopedia.
Katie J. Doores
Born
Katherine Jane Doores

NationalityBritish
EducationUniversity of Oxford
OccupationBiochemist
Years active2007-present

Katherine Jane Doores is a British biochemist who is a senior lecturer in the School of Immunology & Microbial Sciences at King's College London. During the COVID-19 pandemic Doores studied the levels of antibodies in patients who had suffered from COVID-19.[1]

Early life and education

Doores was born in the United Kingdom. In 2003, Doores received an MChem in chemistry from the University of Oxford. In 2008, Doores received a PhD in organic chemistry from the University of Oxford. Ben G. Davis was her advisor.[2] In 2013, she completed post doctoral work in the Department of Immunology and Microbial Sciences at the Scripps Research Institute in La Jolla, California.[citation needed]

Research and career

When Doores was a graduate student at Oxford, she studied

broadly-neutralizing antibodies.[4] At Scripps, Doores worked alongside Dennis Burton, where she studied the "flower-like" envelope protein on HIV. These envelope protein penetrates host cells and create antibody-resistant glycans.[5] By investigating this envelope protein, Doores looked to identify sites which are involved with viral function. By neutralising sites such as these (the high-mannose patch), Doores hoped to protect against HIV infection.[5][6]

From 2013 to 2017, Doores was a lecturer in the Department of Infectious Diseases at King's College London. Doores was awarded a Medical Research Council fellowship to establish her own laboratory at King's College. She was made a European Molecular Biology Organization (EMBO) Young Investigator in 2017.[7] In 2017, Doores became a senior lecturer in the Department of Infectious Diseases at King's College.[citation needed]

Many disease-causing

BNabs (broadly neutralizing HIV-1 antibodies), and Moores is studying how these antibodies evolve in vivo.[8] This understanding will allow the develop of new vaccines that encourage the generation of antibodies that can protect against pathogenic bacteria.[8]

During the COVID-19 pandemic Doores studied the levels of antibodies in patients who had suffered from COVID-19 in Guy's and St Thomas' NHS Foundation Trust.[9][10] Her research showed that while 60% of COVID-19 patients elicited a strong antibody response, only 17% of them retained this potency three months later.[1][11][12] In some cases, patients entirely lost their antibody response.[1] These results implied that immunity to COVID-19 might be short lived, and that people may become reinfected during a second wave of infection.[1]

Selected publications

References

  1. ^ a b c d Sample, Ian (12 July 2020). "Immunity to Covid-19 could be lost in months, UK study suggests". The Guardian.
  2. OCLC 232193273
    .
  3. ^ "The Davis Group - Former Members". The Davis Group. Retrieved 14 July 2020.
  4. ^ "Viral Glycobiology: Chemistry of Infection and Therapeutics". Royal Society of Chemistry. 13 April 2010.
  5. ^ a b "Hitting a Moving Target: AIDS Vaccine Could Work Against Changeable Site on HIV". News & Views. 14 (17). La Jolla, CA: The Scripps Research Institute. 2 June 2014.
  6. ()
  7. ^ "EMBO welcomes 28 new young investigators". American Association for the Advancement of Science (AAAS). 25 October 2017.
  8. ^ a b c d "The Doores Lab". King's College London. Retrieved 14 July 2020.
  9. .
  10. ^ "Covid-19 antibodies can decline over time, research suggests". King's College London. 13 July 2020.
  11. ^ Newman, Cathy; Doores, Katie (13 July 202). "'Perhaps we're not going to be producing long-term antibody responses that would prevent infection' – Dr Katie Doores, King's College London". Channel 4.
  12. ^ Ellyatt, Holly (14 July 2020). "Immunity to the coronavirus may last only a few months, UK study finds". CNBC.

External links